Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**PGX-TEC-ALG** is a preclinical Ceapro wound-healing program described as a loaded formulation using the company’s Pressurized Gas eXpanded technology and alginate-based material platform. Ceapro’s PGX process creates highly porous, high-surface-area biopolymer structures intended for medicated wound dressings and controlled local drug delivery. Published work from Ceapro collaborators demonstrated that an ibuprofen-loaded, calcium-crosslinked PGX-processed alginate hydrogel scaffold accelerated burn-wound healing in vivo; however, the publicly available pipeline label does not explicitly identify the payload or composition of the exact PGX-TEC-ALG program. ([europepmc.org](https://europepmc.org/article/MED/32522716))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PGX-TEC-ALG.